News
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members ...
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Lars Fruergaard Jørgensen, the boss of Danish pharmaceutical giant Novo Nordisk, explained what impact the drugs can have on users weight in the long run ...
Producing nuclear energy on Danish soil was out of the question for decades. But with Russian aggression and a climate crisis ...
15h
Bangkok Post on MSNNovo Nordisk Leads Danish-Thai Forum on Obesity SolutionsThe Royal Danish Embassy in Thailand, in collaboration with Novo Nordisk Pharma (Thailand) Ltd. ('Novo Nordisk'), organised the first Danish-Thai Obesity Policy Forum, bringing together top ...
15h
Bangkok Post on MSNNovo Nordisk, Nanyang Launch Shoes for Haemophilia AwarenessLtd. (Novo Nordisk), a global healthcare company committed to driving change in chronic diseases, has announced the delivery of unique shoes, produced in collaboration with renowned Thai shoe ...
Saudi Minister of Industry and Mineral Resources Bandar Alkhorayef, during his official visit to Denmark, discussed strategic industrial partnerships ...
12h
inews.co.uk on MSN'An act of war': How China's stranglehold on antibiotics could imperil the UKWith China now controlling some 80 per cent of the key chemicals used to make the world’s supply of vital medicines, there ...
The headquarters is located in Copenhagen (Denmark) with offices in San Francisco, Boston and Singapore. The total assets of Novo Holdings amount to 108 billion euros. Novo Nordisk is a corporate fund ...
We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results